130 related articles for article (PubMed ID: 37121015)
1. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
Potere N; Di Nisio M; Porreca E; Wang TF; Tagalakis V; Shivakumar S; Delluc A; Mallick R; Wells PS; Carrier M
Thromb Res; 2023 Jun; 226():82-85. PubMed ID: 37121015
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.
Wang TF; Mallick R; Carrier M; Wells PS
Thromb Res; 2022 Mar; 211():85-87. PubMed ID: 35124234
[TBL] [Abstract][Full Text] [Related]
4. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial.
Knoll W; Mallick R; Wells PS; Carrier M
Thromb Res; 2021 Jan; 197():13-15. PubMed ID: 33160115
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
7. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial.
Nayak AL; Zahrai A; Mallick R; Wang TF; Delluc A; Castellucci LA; Carrier M; Wells PS
Thromb Res; 2021 Dec; 208():79-82. PubMed ID: 34742140
[TBL] [Abstract][Full Text] [Related]
9. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
[TBL] [Abstract][Full Text] [Related]
10. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial.
Ladha D; Mallick R; Wang TF; Caiano L; Wells PS; Carrier M
Thromb Res; 2021 Jun; 202():151-154. PubMed ID: 33857789
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
Muñoz AJ; Ortega L; Gutiérrez A; Gallardo E; Rubio-Rodríguez D; Rubio-Terrés C; Morón B; García-Alfonso P; Soria JM
J Med Econ; 2023; 26(1):1145-1154. PubMed ID: 37602646
[TBL] [Abstract][Full Text] [Related]
17. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW
Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
19. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.
Cohen AT; Pan S; Byon W; Ilyas BS; Taylor T; Lee TC
Adv Ther; 2021 Jun; 38(6):3003-3018. PubMed ID: 33890242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
